CD228 and 4-1BB-directed Antibody-Anticalin® Bispecific Protein
PF-08046049 is an investigational compound. Its safety and efficacy have not been established
Overview + Rationale
- PF-08046049 is an investigational costimulatory bispecific molecule composed of a CD228-directed antibody and 4-1BB-directed Anticalin® proteins designed to provide a costimulatory bridge between tumor-reactive cytotoxic T cells and CD228-expressing tumor cells1
- PF-08046049 targets CD228 (melanotransferrin), which has minimal expression in normal tissue and is selectively expressed by multiple tumor types including melanoma, non-small cell lung cancer, colorectal cancer, pancreatic cancer, and mesothelioma1,2
- 4-1BB is an inducible costimulatory immune receptor expressed on activated T cells and other immune cell populations3,4
Mechanism of Action

Stage of Development
Advanced Melanoma
Phase 1 Monotherapy*